262 results on '"d'Oiron R"'
Search Results
2. Perioperative management and neuraxial analgesia in women with factor XI deficiency (
3. Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU
4. Bleeding phenotype according to factor level in 825 children with non-severe hemophilia; data from the PedNet cohort
5. Imaging features of atypical bleeds in young patients with hemophilia
6. LB 01.1 Efanesoctocog Alfa Prophylaxis for Previously Treated Patients <12 Years of Age with Severe Hemophilia A
7. PB0680 Clinical Characteristics, Therapy and Outcome of Children with Hemophilia B and Inhibitors: a PedNet Study
8. OC 43.1 A Survey on Clinical Praxis in Initiating Emicizumab Prophylaxis in Previously Untreated Patients in the PedNet Centers
9. Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU
10. Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study
11. European principles of inhibitor management in patients with haemophilia: implications of new treatment options
12. Efficacy and safety of high ration HVWF/FVIII concentrate (VONCENTO (R)) for the treatment of bleeding epidodes in patients with WITH VON WILLEBRAND disease :s: the OPALE French experience
13. Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII‐specific T cells
14. Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014
15. Plasma-derived factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A: report of the FranceCoag Network: OR143
16. Characterization of four novel molecular changes in the promoter region of the factor VIII gene
17. Cancer detection and management in patients with haemophilia: a retrospective European multicentre study
18. Treatment of girls and women with haemophilia A and haemophilia B: a retrospective study in the francecoag cohort
19. Treatment modalities and outcomes in 870 nonsurgical bleeds in 184 Glanzmann thrombasthenia (GT) patients. The International Prospective Glanzmannʼs Thrombasthenia Registry (GTR): PO 498
20. Impact of haemophilia on cancer detection and management: a retrospective study: PB 4.60–6
21. ORTHem 15–25: French retrospective national survey of different treatment regimens in patients with severe (factor VIII or IX = 2%) haemophilia A and B between 15 and 25 years old: PB 4.36–5
22. Treatment modalities and outcomes in 204 surgical procedures in 96 Glanzmann thrombasthenia (GT) patients: the International Prospective Glanzmannʼs Thrombasthenia Registry (GTR): OC 34.4
23. Use of Haemate® P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study
24. Molecular analysis of the fibrinogen gene cluster in 16 patients with congenital afibrinogenemia: novel truncating mutations in the FGA and FGG genes
25. Malignant disease in the haemophilic population: moving towards a management consensus?
26. A Web Based Integrated System for Recording Health Events and Musculo- Articular Assessments and Scoring for Hemophilia Patients: PO-WE-181
27. Incidence of Hemophiliac Arthropathy in Moderate and Mild Hemophilia Patients: A Retrospective Study from Paris-Bicêtre Hospital: PO-WE-162
28. Spectrum of mutations in 345 unrelated hemophilia B patients: PO-MO-141
29. Update data of the FranceCoag Network, the French National Registry for Congenital Bleeding Disorders: PO-MO-024
30. How I treat inhibitors in haemophilia
31. Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition
32. Glanzmann thrombasthenia registry (GTR): a tool for the development of consensus guidelines for the management of Glanzmannʼs thrombasthenia (GT): 28P07
33. Molecular analysis of haemophilia: guidelines from the French Haemophilia Care Centre Network: 21P25
34. Incidence of inhibitor in mild/moderate haemophilia (MH) patients within the FranceCoag Network: 20P03
35. Risk factors of inhibitor in 321 PUPs with severe haemophilia A: results of the FranceCoag Network: 17P18
36. Session W1.4 Factor VIII light chain mutations and cysteine substitutions predispose for inhibitor development in mild and moderate haemophilia A: first results from the INSIGHT study: 17FP05
37. Conditions of birth of severe hemophilia patients in Paris area: a series of 86 patients: 06P34
38. The second Team Haemophilia Education Meeting, 2016, Frankfurt, Germany
39. Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations
40. Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development
41. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors
42. Diagnosis of severe hemophilia remains frequently delayed in Paris area: 16 PO 473
43. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey
44. First identification and expression of a type 2N von Willebrand disease mutation (E1078K) located in exon 25 of von Willebrand factor gene
45. Protein A sepharose immunoadsorption: immunological and haemostatic effects in two cases of acquired haemophilia
46. Molecular mechanisms of mild and moderate hemophilia A
47. Demographic and clinical data in acquired hemophilia A
48. Metabolic, hepatic and muscular changes during zidovudine therapy: a drug-induced mitochondrial disease?
49. Quality of Life in Patients with Congenital Afibrinogenaemia: The Qualyafib Study
50. Common themes and challenges in hemophilia care: a multinational perspective
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.